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1, INTRODUCTION 
The anthracyclines adriamycin (ADR, dox- 
orubicin) and daunornbici~ are antineopIastic an- 
tibiotics with substantial therapeutic activity 
against a wide variety of human malignancies, in- 
cluding cancers of the breast, ovary and the lym- 
phatic system [I]. Unfortunately, the total dose of 
these agents that can be administered is severely 
limited by a unique type of cardiac toxicity which 
may be the direct result of drug-induced free 
radical formation [2,3]. Both cardiac sarcosomes 
[2] and mitochondria [2,3] can reduce ADR and 
daunorubicin to their respective semiquinones, in- 
itiating a free radical cascade which heart tissue, 
with its Iimited antioxidant defenses 141, seems 
unable to resist. Thayer [3] suggested initially that 
NADH dehydrogenase was the mitochondrial site 
of ADR reduction; however, a detailed study of 
this proposal as well as an investigation of the 
range of drug-related oxygen radical metabolism 
by mitochondria has not previously been con- 
ducted. Furthermore, a new anthracycline 
derivative, 5iminodaunorubicin (%IDR), with 
promising antitumor activity [5] and distinctly dif- 
ferent redox properties from those of ADR [5,6] 
has been synthesized as a potentially non- 
cardiotoxic anthracycline analogue for use in 
cancer chemotherapy. Hence, in this study we have 
attempted to define both the site of anthracycline 
reduction in the electron transport chain, and the 
nature and extent of reactive oxygen production 
stimulated by ADR and 5-IDR. 
2, MATERIALS AND METHODS 
* Present address: Department of Physiology and 
Biophysics, Harvard Medical School, 25 Shattuck St., 
Boston, MA 02115, USA 
Abbreviations: BH-SMP, beef heart submitochondrial 
particles (preparations); ADR, adriamycin (dox- 
orubicin); 5-IDR, 5iminodaunorubicin; O;-, superox- 
ide anion; OH’, hydroxyl radical 
Beef heart submitochondrial particles (BH- 
SMP) were prepared by established procedures [7]. 
Oxygen consumption was measured 
polarogra~hic~Iy [2,8,9], and NADH oxidation 
was assayed spectrophotometricalIy by absorbance 
decrease at 340 nm [8,9]. Reduction of exogenous 
NAD+ to NADH during BH-SMP reverse electron 
transport was energized by ATP, using succinate 
as the electron source, in the presence of an an- 
timycin A block [9]. Anthracycline radicals were 
detected by EPR spectroscopy (Varian E-3) at 
25”C, and the spin trap, 5,5-dimethyIpyrroline-~- 
oxide (DMPO) was used to estimate hydroxyl 
radical (OH’) production [IO]. The superoxide 
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radical was measured as superoxide dismutase- 
inhibitable, acetylated cytochrome c reduction [2]. 
Hydrogen peroxide was determined by the return 
of oxygen, to a closed system, following catalase 
addition [2]. ADR was purchased from Adria Labs 
(Columbus OH) and 5-IDR was supplied by the 
Drug Synthesis and Chemistry Branch, National 
Cancer Inst. (Bethesda MD). 
3. RESULTS 
Addition of ADR to BH-SMP respiring on 
NADH (in the absence of rotenone) caused a 
15-20070 decrease in maximal rates of 02 consump- 
tion and NADH oxidation; 5-IDR, however, was 
without significant effect (table 1). In the absence 
of anthracycline, rotenone decreased BH-SMP 
NADH oxidation and 02 consumption to only 
2-3% of the non rotenone-inhibited rates. Addi- 
tion of ADR to rotenone-inhibited BH-SMP in- 
creased the rates of NADH oxidation and 02 con- 
sumption dramatically, but 5-IDR was, again, 
without effect. These results were not altered by 
the addition of KCN; and succinate could not 
substitute for NADH as the electron source. 
Piericidin A or amytal produced essentially the 
same results as did rotenone. The same trends were 
also seen with freshly prepared, intact, mitochon- 
dria respiring on pyruvate plus malate (not 
shown). 
subsequently reduces molecular oxygen (accoun- 
ting for the 02 consumption in the presence of 
rotenone, piericidin A, amytal or KCN). If this 
hypothesis is correct, ADR should also be reduced 
by NADH dehydrogenase during ATP-energized 
reverse electron transport from succinate to 
NAD+. Indeed, in table 2, it is seen that ADR in- 
hibited NAD’ reduction during reverse electron 
transport by some 70%, and that the process con- 
sumed oxygen. In contrast, 5-IDR had only a 
minor effect on NAD+ reduction and did not in- 
duce 02 consumption. NAD+ reduction was com- 
pletely inhibited by rotenone or 
thenoyltrifluoroacetone, and these agents also 
blocked the ADR-induced 02 consumption. Fur- 
thermore, KCN did not decrease 02 consumption 
produced by ADR, thus ruling out a possible 
electron-transport chain bypass to cytochrome 
oxidase. 
That ADR undergoes a one-electron reduction 
by mitochondrial NADH dehydrogenase was 
demonstrated by the production of an ADR free 
radical (fig.1). The ADR radical (g 2: 2.004, peak 
to peak signal width = 4.5 G) exhibited no hyper- 
fine structure, and was more stable under 
anaerobic than aerobic conditions. No 5-IDR 
radical could be discerned at 0.1, 0.2 or 0.3 mM 
drug concentration; however, a weak signal was 
evident at 0.5 mM 5-IDR (< 10% of that seen with 
0.2 mM ADR). 
The data of table 1 indicate that ADR undergoes In the presence of ADR and NADH, rotenone- 
reduction via a component of NADH inhibited BH-SMP produced Oi-, H202, and OH’ 
dehydrogenase (mitochondrial complex I) and (table 3). The production of all three activated ox- 
Table 1 
Effects of anthracyclines on NADH respiration by beef heart SMP 
Anthracycline 
added 
02 consumptiona 
- Rotenone + Rotenone 
NADH oxidationb 
- Rotenone + Rotenone 
None 268 + 13 4+ 1 64 +- I 2-t 1 
Adriamycin 226 + 12 116 f 8 53 +- 9 30 * 4 
5Iminodaunorubicin 259 f 11 9+2 62 t 9 351 
a nmol Oz.min-’ .mg BH-SMP-’ at 37°C 
b nmol NADH . mini .mg BH-SMP-’ at 23°C 
Results are I’,,,,, values (mean k SE) obtained by Lineweaver-Burk extrapolation (anthracycline range O-O.6 mM, 
NADH range O-2 mM) in 0.1 M KP04 buffer (pH 7.2) + 0.01 mM rotenone 
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Table 2 Table 3 
Effects of anthracyclines on reverse lectron transport 
from succinate to NAD+ by BH-SMP 
Superoxide, hydrogen peroxide, and hydroxyl radical 
production by rotenone-inhibited beef heart SMP 
Anthracycline NADH Oxygen 
added production consumption 
None 38 + 3 2+1 
Adriamycin 11 f 1 50 rt: 6 
5-Iminodaunorubicin 30 f 2 3+2 
Values are nmol NADH produced or 02 
consumed. min-’ . mg BH-SMP-’ (mean + SE). 
Temperature was 23°C for NADH and 37*C for OZ. 
Results obtained in 0.1 M KPOd (pH 7.2), with 10 mM 
succinate, 0.04 mM antimycin A, and 5 mM ATP, + 
0.2 mM anthracycline 
Fig.1. EPR spectra of ADR and 5-IDR incubated with 
BH-SMP. ADR and S-IDR were 0.2 mM in 0.1 M KPOJ 
(pH 7.2), plus 10 mM NADH and 0.01 mM rotenone. 
EPR conditions: 100 kHz field; 9.45 GHz microwave 
frequency; 3 mW microwave power; 4 G modulation; 
0.3 s time constant; 8 min scan time; 50 G scan range; 
at 25T. 
ygen species was inhibited by superoxide dismutase 
(not shown). Conversely, rotenone-inhibited BH- 
SMP supplemented with NADH and 5-IDR pro- 
duced barely detectable Ievels of Oi- or OH’ 
(2 7% of that seen with ADR), and no detectable 
H202. 
Anthracycline Superoxidea Hydrogen Hydroxyl 
added peroxideb radicalc 
None 0 & 0 0.26 + 0.26 o+o 
Adriamycin 67 + 3 1.34 + 0.24 116 + 9 
S-Iminodauno- 
rubicin 5 f 1 0.00 Z!Z 0.00 8~1 
a nmol acetylated cytochrome c reduced. min- ’ . mg BH- 
SMP-’ at 37*C 
b Percent of total 02 consumed which was returned to 
system by 1500 units/ml catalase addition 
’ Relative EPR signal height (arbitrary units) of DMPO- 
OH’ adduct at 25°C 
Results (mean zt SE) obtained in 0.1 M KP04 (pH 7.2) 
with 0.2-2.0 mM NADH, 0.02-0.10 mM rotenone, and 
0.2 mM anthracycline 
4. DISCUSSION 
Our results demonstrate that a component of 
mitochondrial NADH dehydrogenase actively 
reduces ADR, whereas 5-IDR is relatively unreac- 
tive. The reaction sequence for ADR appears to be 
an initial one-electron reduction to produce an 
ADR’ radical. The drug-based free radical then 
reduces molecular oxygen, producing Oi- and 
regenerating the oxidized ADR, establishing an 
ADR redox cycle. Some of the Oi- so produced 
undergoes ..dismutation to yield H202. Hydroxyl 
radical detected under our experimental conditions 
may be the result of an iron-catalyzed 
Haber-Weiss reaction, which could also produce 
singlet oxygen [ 111. We propose that a simiIar free- 
radical cascade is responsible for the marked tox- 
icity of ADR for cardiac mitochondrial mem- 
branes [ 11. 
S-IDR appears to be poorly reduced by 
mitochondria~ NADH dehydrogenase and, as 
might be expected from previous chemical studies 
[5,6], has a very limited tendency to auto-oxidize. 
Thus, unlike ADR, 5-IDR does not participate to 
any significant extent in NADH dehydrogenase- 
mediated free radical redox cycles. This is pro- 
bably due to the imine substitution on the quinone 
ring. These findings are supported by data sug- 
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gesting that 5-IDR is poorly reduced by liver 
microsomes [5], which actively redox cycle ADR 
and daunorubicin. Since 5-IDR retains antitumor 
activity against P388 leukemia while inhibiting 
DNA and RNA synthesis in L1210 cells [6], 5-IDR 
could prove to be an effective, non-cardiotoxic 
alternative to other currently available an- 
thracycline anticancer agents. 
Previous work with the anthracyclines has large- 
ly concentrated on free radical generation by the 
NADPH cytochrome P450 reductase system of 
liver endoplasmic reticulum (microsomes) and car- 
diac sarcoplasmic reticulum (sarcosomes) [ 12-141. 
While such studies have provided extremely 
valuable models, it is now appropriate to begin a 
careful assessment of the relative contributions of 
cardiac mitochondria and sarcoplasmic reticulum 
to anthracycline toxicity. Specific activities for 
ADR reduction and Oi- production were found to 
be L 100% higher for (intact) cardiac mitochon- 
dria than for cardiac sarcosomes, in a direct com- 
parison [2]. Using identical methods, specific ac- 
tivities for oxygen radical production by BH-SMP 
here are substantially higher than those found for 
either heart mitochondria or sarcosomes in [2]. 
This, coupled with the high mitochondrial content, 
and the NADH/NADPH ratio of cardiac muscle 
in vivo [15], suggests that drug-related free radical 
formation by mitochondrial NADH 
dehydrogenase may play a major role in the 
etiology of anthracycline cardiotoxicity. 
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